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OBJECTIVES: We correlated follow-up information from 138
patients with Barrett’s esophagus and varying degrees of
dysplasia with the presence of ulcers.
METHODS: A group of pathologist participants were asked
to contribute patients’ initial biopsy slides showing Barrett’s
esophagus (BE) without dysplasia and with epithelial changes
indefinite for dysplasia, low grade dysplasia (LGD), high grade
dysplasia (HGD), and adenocarcinoma. From the initial 250
cases used for a diagnostic reproducibility study, follow-up
information was available for 138 patients.
RESULTS: There were 44 cases submitted as BE, 22 as BE
with epithelial changes indefinite for dysplasia, 26 as BE
with LGD, 33 as BE with HGD, and 13 as BE with adeno-
carcinoma. Ulcers were present in 35/138 cases (25%),
including 3/44 cases of BE without dysplasia (7%), 2/22
cases of BE with epithelial changes indefinite for dysplasia
(9%), 0/26 cases of BE with LGD (0%), 10/33 cases of BE
with HGD (30%), and 7/13 cases of BE with adenocarci-
noma (54%). On follow-up, there were no invasive carci-
nomas detected among the BE without dysplasia group
(median follow-up 38.5 months). Adenocarcinomas were
detected in 4/22 cases (18%) submitted as BE with epithelial
changes indefinite for dysplasia at 19, 55, 60, and 62 months
and in 4/26 cases (15%) of BE with LGD at 9, 9, 11, and 60
months. None of these carcinomas occurred in cases in
which an ulcer was present in the initial biopsy specimen.
Among the 33 HGD cases, 20 (60%) were found to have
adenocarcinoma on subsequent resection specimens. The
presence of an ulcer with HGD increased the likelihood of
finding carcinoma in the resection specimen, as 8/10 biop-
sies (80%) of HGD patients with ulcers had carcinoma,
compared to 12/23 biopsies (52%) of HGD patients without
ulcers. All of the cases interpreted as adenocarcinomas on
biopsy were found either to have invasive carcinoma on
esophageal resection or to have metastases that were dem-
onstrated in unresectable patients.
CONCLUSION: If an ulcer accompanies HGD in a biopsy spec-
imen from a patient with BE, it is likely that invasive carci-
noma is also present at that time. (Am J Gastroenterol 2002;97:
27–31. © 2002 by Am. Coll. of Gastroenterology)
INTRODUCTION
When physicians first became aware of the entity now
referred to as Barrett’s esophagus (BE), the most notewor-
thy complications were the development of ulcers and stric-
tures (1, 2). As medical therapies directed at acid suppres-
sion have considerably reduced these complications, at
times to the point of masking carcinomas (3), and as the
incidence of esophageal adenocarcinoma has been increas-
ing (4, 5), benign esophageal ulcers and strictures pose
lesser threats to patients with gastroesophageal reflux dis-
ease. We have revisited the significance of identifying
esophageal ulcers in biopsy specimens from patients with
BE in the acid suppression era.
MATERIALS AND METHODS
From a cohort of 250 cases that were used to test established
criteria for grading dysplasia in BE, we obtained follow-up
information on 138 patients. The study was initially a patho-
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logical one, so patients were not enrolled per se and biopsies
were initially chosen from participating pathologists’ insti-
tutional archives to demonstrate histological findings. Con-
sistent information about the endoscopic findings and pa-
tients’ medication histories were not available. Full results
of this follow-up study and results of the intraobserver study
from which the data were derived are reported elsewhere (6,
7). Briefly, each of 10 participants from 10 institutions
contributed slides, all of which were reviewed by 12 ob-
servers (two reviewers did not contribute cases). Each con-
tributor was instructed to supply slides from the initial
known endoscopic biopsies of patients having the follow-
ing: 1) BE without dysplasia (goblet cells present above the
gastroesophageal junction), 2) BE with inflammation and/or
inflammatory atypia, 3) BE with epithelial changes indefi-
nite for dysplasia, 4) BE with low grade dysplasia (LGD), 5)
BE with high grade dysplasia (HGD), 6) intramucosal car-
cinoma in BE, or 7) frankly invasive esophageal adenocar-
cinoma. However, because many of the biopsies were from
referral centers, it is possible that some of the patients could
have had prior biopsies and results were unavailable.
All 250 cases were reviewed blindly on two separate
occasions by all 12 pathologists, and thus 24 diagnostic
opinions were available for each case. Masked slides were
circulated with a worksheet that asked participants to assign
a grade to each case using the following scale: 0  BE with
no dysplasia, 1  epithelial changes indefinite for dysplasia,
2  LGD, 3  HGD, 4  intramucosal carcinoma, and 5 
frankly invasive carcinoma. All cases were also separately
evaluated by one of the reviewers (E.M.) for the presence or
absence of ulcers. Ulcers were defined on strictly histolog-
ical grounds—namely, by the presence of necroinflamma-
tory exudate extending the full thickness of the mucosa
(surface to muscularis mucosae).
Patients did not have their cases followed on rigorous
biopsy protocols (8, 9), and thus it was understood that there
would be variations in sampling. It was also understood that
knowledge of the endoscopic findings and presenting symp-
toms that led to biopsy would not be uniformly documented.
Participants submitted a follow-up worksheet requiring
completion of the following data points: patient demo-
graphic data (age, gender, race), date of submitted biopsy,
follow-up biopsy/specimen date, findings in follow-up bi-
opsy or resection, interval between submitted biopsy and
Figure 1. Area of ulcer in a case submitted to the diagnostic variability study as HGD. HGD without invasive carcinoma was found on
the subsequent resection specimen.


















No dysplasia 44 38.5 (1–78) 3/44 (7%) 0/3 0 (0%)
Indefinite for dysplasia 22 36 (7–144) 2/22 (9%) 0/2 4 (18%)
LGD 26 24 (2–72) 0 (0%) 0/0 4 (15%)
HGD 33 13 (1–60) 10/33 (30%) 8/10 (80%) 20 (61%)
Carcinoma 13 4.4 (1–22) 7/13 (54%) 7/7 (100%) 13 (100%)
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follow-up biopsy or resection (months), patient status (alive
or dead), and last follow-up date. Follow-up information
was correlated with the presence of ulcers and categories
compared using Fisher’s exact test. Full analysis of Kaplan-
Meier curves is reported elsewhere (6).
RESULTS (TABLE 1)
Overall, invasive carcinoma was found in 15/22 (68%) of
patients whose biopsy specimens demonstrated an ulcer, but
only in 20/116 (17%) cases without.
Summary of Ulcers by Diagnostic Category
Ulcers were only found in 7% of all biopsy specimens
interpreted as negative for dysplasia and in 9% of cases of
BE with epithelial changes indefinite for dysplasia, and were
not identified in the LGD cases. On the other hand, ulcers
were found in 30% of HGD and in 54% of carcinoma cases.
Negative for Dysplasia
On follow-up, there were no invasive carcinomas detected
among the 44 patients in the BE without dysplasia group
during the follow-up period (median follow-up  38.5
Figure 2. Nonulcerated area (A) and ulcerated one (B) in specimen submitted as HGD. Invasive carcinoma was detected on the resection
specimen.
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months). Three of the 44 patients (7%) in this category had
ulcers.
Indefinite for Dysplasia
Adenocarcinomas were detected in 4/22 cases (18%) sub-
mitted as BE with epithelial changes indefinite for dysplasia
at 19, 55, 60, and 62 months (median follow-up  36
months). Two of the 22 patients (9%) in the BE with
epithelial changes indefinite for dysplasia category had ul-
cers, but the patients who progressed were not the two with
ulcers on their initial biopsies.
Low Grade Dysplasia
Adenocarcinomas developed in 4/26 cases (15%) of LGD at
9, 9, 11, and 60 months (median follow-up  24 months).
No patients diagnosed with LGD had ulcers on their initial
biopsies.
High Grade Dysplasia
Among the 33 HGD cases, 20 (60%) were found to have
adenocarcinomas on subsequent resection specimens (me-
dian follow-up  13 months). Ten of the 33 (30%) had
ulcers. The presence of an ulcer with HGD (Figs. 1 and 2)
increased the likelihood of finding carcinoma in the resec-
tion specimen, as 8/10 biopsy specimens (80%) with HGD
and ulcers had carcinoma in the resection specimen, com-
pared to 12/23 (52%) biopsy specimens with HGD and no
ulcers (Fig. 3) (p  0.24, Fisher’s exact test).
Adenocarcinoma
All of the cases interpreted as adenocarcinoma on biopsy
were found either to have invasive carcinoma on esophageal
resection or to have metastases that were demonstrated in
unresectable patients. Ulcers were common among patients
diagnosed initially with adenocarcinoma (7/13, 54%).
DISCUSSION
Despite its limitations (7, 10), routine histological evalua-
tion remains the major prognostic tool in identifying the
subset of BE patients at highest risk for development of
invasive esophageal carcinoma (6, 11). Some observers
regard HGD as a surveillance endpoint that should prompt
esophagectomy (12, 13). However, with intensive endo-
scopic surveillance including numerous biopsies, some phy-
sicians performing endoscopy are willing to observe pa-
tients with HGD in whom accompanying invasive
carcinoma has been carefully excluded (8, 9), because only
about 60% will develop invasive adenocarcinoma within 5
yr (11), usually at an early stage. However, it is well known
that patients having prevalent HGD, or HGD identified at
their initial endoscopies and therefore present for an un-
known period of time, are likely to also harbor invasive
carcinoma that is detected on further sampling or on resec-
tion. This is highlighted in a recent publication by Schnell et
al. (14). In summarized surgical series, 43% of patients are
found to harbor an occult invasive carcinoma upon esoph-
ageal resection for HGD (15). However, the frequency with
which unsuspected carcinoma is identified in patients un-
dergoing esophagectomy for HGD ranges from 0% to 73%
(15).
The current study, derived from a group of patients whose
mucosal biopsies were used to test observer variability in
grading dysplasia, indicates that the presence of an ulcer
accompanying prevalent HGD strongly suggests that the
patient harbors an invasive lesion. Invasive carcinoma was
found in 15/22 patients (68%) whose biopsy specimens
demonstrated an ulcer, but only in 20/116 cases (17%)
without. Obviously, this summary of our data has no bearing
on the true incidence of carcinoma accompanying ulcers in
the general Barrett’s population because dysplasia and car-
cinoma occur in a minority of patients and our cases in-
cluded many examples of dysplasia and known invasive
carcinoma. However, the key finding in our study is that
80% of patients with HGD and an ulcer were found to have
invasive carcinoma on resection or by documentation of
metastases, whereas about 50% of those with HGD without
ulcers were found to have adenocarcinomas on resection.
Although this difference did not reach statistical signifi-
cance (p  0.24 by Fisher’s exact test), presumably because
of relatively small numbers, the figure is alarming and
indicates a trend. Other observers have previously noted an
association between ulcers and invasive carcinomas in both
gastric and esophageal dysplasias resected for the indication
of HGD (16).
Although severe erosive esophagitis and strictures were
the primary complications of BE in the past (1, 2), in the
acid suppression era, ulcers are readily healed. In our group
of cases, ulcers were only found in 7% of all biopsy spec-
imens interpreted as negative for dysplasia and in 9% of
cases with changes indefinite for dysplasia, and were not
identified in the low grade cases. On the other hand, ulcers
were found in 30% of our cases with HGD and in over half
of the carcinoma cases. BE patients with ulcers warrant
close attention and multiple biopsies to exclude occult in-
vasive carcinoma. Patients with HGD and ulceration are
highly likely to have synchronous invasive carcinoma.
Figure 3. Identification of carcinoma in resected specimens from
patients with HGD.
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